CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤疫苗肿瘤治疗研究进展
英文原题：Glioblastoma vaccine tumor therapy research progress.
查看英文原题
Glioblastoma vaccine tumor therapy research progress.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）是成人中最常见的中枢神经系统原发性恶性肿瘤。晚期胶质母细胞瘤（世界卫生组织IV级星形细胞胶质瘤）的预后非常差。临床医生和研究人员一直在寻找和评估新的治疗方案，在外科技术、放疗和化疗方面已取得显著进展。然而，胶质母细胞瘤的治疗仍然极其困难，只能将患者的生命延长几个月。在免疫治疗领域，特别是肿瘤疫苗的使用方面，治疗胶质母细胞瘤已取得显著进展；尤其是肽疫苗和基于细胞的疫苗，如树突状细胞疫苗和肿瘤细胞疫苗。然而，目前疫苗接种临床试验的结果并不令人满意。本文综述了胶质母细胞瘤疫苗开发的进展。
展开英文摘要原文
Glioblastoma (GBM) is the most common primary malignancy of the central nervous system in adults. The prognosis for late-stage glioblastoma (World Health Organization grade IV astrocytic glioma) is very poor. Novel treatment options are sought after and evaluated by clinicians and researchers, and remarkable advances have been made in surgical techniques, radiotherapy, and chemotherapy.
However, the treatment of glioblastoma remains extremely difficult and it can extend the lives of patients by only a few months. There has been notable progress in the field of immunotherapy, particularly with the use of tumor vaccines, for treating glioblastoma; especially peptide vaccines and cell-based vaccines such as dendritic cell vaccines and tumor cell vaccines.
However, the results of the current clinical trials for vaccination are not satisfactory. This article reviews the progress in the development of vaccines for glioblastoma.
论文信息
- 作者
- Zhao T、Li C、Ge H、Lin Y、Kang D
- 第一作者单位
- Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, People's Republic of China.China
- 通讯作者单位
- Department of Neurosurgery, Neurosurgery Research Institute, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian Province, People's Republic of China. kdz99988@vip.sina.com.China
- 文献类型
- 综述
- 期刊
- Chinese neurosurgical journal2022 Jan 19
- 原文标识
- PubMed 35045874 · DOI 10.1186/s41016-021-00269-7
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →